Your browser doesn't support javascript.
loading
Use of LC-MS/MS to cross-validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrastat (tirofiban hydrochloride) in human plasma.
Ellis, J D; Hand, E L; Gilbert, J D.
Afiliação
  • Ellis JD; Department of Drug Metabolism I, Merck Research Laboratories, West Point, PA 19486, USA.
J Pharm Biomed Anal ; 15(5): 561-9, 1997 Feb.
Article em En | MEDLINE | ID: mdl-9127267
ABSTRACT
A method based on LC-MS/MS was developed for the determination of the fibrinogen-receptor antagonist Aggrastat in human plasma. The drug is isolated from plasma by liquid extraction and converted into its N-trifluoroacetyl derivative prior to analysis by HPLC with atmospheric pressure negative chemical ionization MS/MS detection. A structural analog is used as the internal standard and the lower quantifiable limit of the assay is 0.4 ng ml-1 with a relative standard deviation of 7%. This assay was used to cross-validate the existing immunoassay by analysis of plasma from patients receiving the drug. The specificity of the immunoassay was thereby confirmed.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Tirosina / Inibidores da Agregação Plaquetária / Complexo Glicoproteico GPIIb-IIIa de Plaquetas / Fibrinolíticos Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: J Pharm Biomed Anal Ano de publicação: 1997 Tipo de documento: Article País de afiliação: Estados Unidos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Tirosina / Inibidores da Agregação Plaquetária / Complexo Glicoproteico GPIIb-IIIa de Plaquetas / Fibrinolíticos Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: J Pharm Biomed Anal Ano de publicação: 1997 Tipo de documento: Article País de afiliação: Estados Unidos